Clinical DataClinical data for Givastomig shows an 83% overall response rate, which is favorable compared to the approximately 40% response rate of a competitor's treatment.
Enrollment ProgressEnrollment in the Givastomig dose expansion cohorts is ahead of schedule, indicating strong interest and potential progress in the study.
Safety ProfileGivastomig continues to demonstrate a differentiated and manageable safety profile, with no dose-limiting toxicities or grade 4/5 TRAEs, and only isolated grade 3 events.